Clinical Trial: A Phase 2, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07078955) titled 'A Phase 2, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease' on July 14.

Brief Summary: To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to vehicle for treatment of the signs and symptoms of dry eye disease (DED)

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Dry Eye Disease (DED) Keratoconjunctivitis Sicca

Intervention: DRUG: BRM421 Ophthalmic Solution, 0.03%

A topical drop of 0.03% BRM421 ophthalmic solution.

DRUG: Vehicle Ophthalmic S...